transplant rejection
Natera Q1 Revenues Grow 62 Percent
The company reported $152.3 million in total revenues for the quarter and said the number of tests it processed rose 48 percent from the prior-year quarter.
CareDx Q1 Revenues up 76 Percent
The company reported $67.4 million in total revenues for the quarter and said testing service revenues rose 89 percent year over year.
NY State Department of Health Approves Eurofins Viracor Transplant Rejection Tests
The Viracor TRAC donor-derived cell-free DNA test and TruGraf blood gene expression test both assess rejection status in kidney transplant recipients.
Following the launch of its urine-based Qsant assay later this year, the firm plans to develop updated versions of it with new biomarkers for different disease indications. Â
CareDx Acquires European Transplant Surveillance Software Firm BFS Molecular
The company uses next-generation sequencing data to track the health of transplanted organs and stem cells over time.
Mar 16, 2021
NephroSant Raises $16M in Series A Funding Round
Feb 25, 2021
Feb 24, 2021
CareDx Q4 Revenues Up 64 Percent
Jan 27, 2021
Oct 29, 2020
CareDx Q3 Revenues Up 58 Percent
Oct 7, 2020
CareDx Preliminary Q3 Revenues Up 57 Percent
Aug 4, 2020
CareDx Q2 Revenues Up 33 Percent
Jun 26, 2020